Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer
- Oregon Health Sciences Univ., Portland, OR (United States)
- Univ. of California San Francisco, San Francisco, CA (United States)
- Netherlands Cancer Institute, Amsterdam (The Netherlands); Univ. of Warwick, Coventry (United Kingdom)
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- Univ. of California, Berkeley, CA (United States)
- Oregon Health Sciences Univ., Portland, OR (United States); Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- MD Anderson Cancer Center, Houston, TX (United States)
- Netherlands Cancer Institute, Amsterdam (The Netherlands); German Center for Neurodegenerative Diseases, Bonn (Germany)
- Univ. of Texas, Houston, TX (United States). MD Anderson Cancer Center.
We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2+ breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 HER2+ breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combinations of lapatinib plus AKTi were synergistic in HER2/PIK3CAmut cell lines but not in HER2+/PIK3CAwt cell lines. We measured changes in phospho-protein levels in 15 cell lines after treatment with lapatinib, AKTi or lapatinib + AKTi to shed light on the underlying signaling dynamics. This revealed that p-S6RP levels were less well attenuated by lapatinib in HER2+/PIK3CAmut cells compared to HER2+/PIK3CAwt cells and that lapatinib + AKTi reduced p-S6RP levels to those achieved in HER2+/PIK3CAwt cells with lapatinib alone. We also found that that compensatory up-regulation of p-HER3 and p-HER2 is blunted in PIK3CAmut cells following lapatinib + AKTi treatment. Responses of HER2+ SKBR3 cells transfected with lentiviruses carrying control or PIK3CAmut sequences were similar to those observed in HER2+/PIK3CAmut cell lines but not in HER2+/PIK3CAwt cell lines. We used a nonlinear ordinary differential equation model to support the idea that PIK3CA mutations act as downstream activators of AKT that blunt lapatinib inhibition of downstream AKT signaling and that the effects of PIK3CA mutations can be countered by combining lapatinib with an AKTi. This combination does not confer substantial benefit beyond lapatinib in HER2+/PIK3CAwt cells.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- USDOE; National Cancer Institute (NCI)
- Grant/Contract Number:
- AC02-05CH11231
- OSTI ID:
- 1212476
- Journal Information:
- PLoS ONE, Vol. 10, Issue 7; ISSN 1932-6203
- Publisher:
- Public Library of ScienceCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Delineating feedback activity in the MAPK and AKT pathways using feedback-enabled Inference of Signaling Activity
|
posted_content | February 2018 |
GRB7 dependent proliferation of basal‐like, HER‐2 positive human breast cancer cell lines is mediated in part by HER‐1 signaling
|
journal | January 2019 |
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes
|
journal | March 2018 |
Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution
|
journal | November 2017 |
Similar Records
An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib